Chronic cannabis (marijuana, hashish) smoking can result in dependence. Rodent studies show reversible downregulation of brain cannabinoid CB 1 (cannabinoid receptor type 1) receptors after chronic exposure to cannabis. However, whether downregulation occurs in humans who chronically smoke cannabis is unknown. Here we show, using positron emission tomography imaging, reversible and regionally selective downregulation of brain cannabinoid CB 1 receptors in human subjects who chronically smoke cannabis. Downregulation correlated with years of cannabis smoking and was selective to cortical brain regions. After B4 weeks of continuously monitored abstinence from cannabis on a secure research unit, CB 1 receptor density returned to normal levels. This is the first direct demonstration of cortical cannabinoid CB 1 receptor downregulation as a neuroadaptation that may promote cannabis dependence in human brain.
Introduction
Cannabis is the most widely used illicit drug in the world 1 and causes multiple health problems. 2 Chronic cannabis smoking can lead to tolerance [3] [4] [5] and withdrawal symptoms, 6, 7 the two hallmarks of dependence. In human brain, the actions of the main psychoactive component of cannabis, D
9
-tetrahydrocannabinol (D 9 -THC), are mediated via cannabinoid CB 1 (cannabinoid receptor type 1) receptors. 8, 9 CB 1 receptors are widely distributed in human brain, and highest receptor densities are found in basal ganglia, hippocampus, cingulate cortex and the molecular layer of cerebellum.
10,11 CB 1 receptors are primarily located presynaptically, where they inhibit release of other neurotransmitters, such as glutamate and g-amino butyric acid. 12, 13 However, the exact role of CB 1 receptors in the development of tolerance and withdrawal in humans is unclear.
In rodent brain, downregulation of CB 1 receptor signaling is thought to underlie tolerance. 14 That is, chronic exposure to D
-THC and other cannabinoid agonists causes a reduction in the number and signaling efficiency of CB 1 receptors as a homeostatic response. [15] [16] [17] [18] [19] [20] [21] These changes closely parallel development of tolerance to typical cannabinoid effects, such as decreased motility and impaired memory. 15 The magnitude and rate of downregulation are region dependent. The downregulation is larger and occurs more rapidly in cortical regions, such as hippocampus and cerebellum, than in subcortical regions, such as basal ganglia and midbrain. 15 In addition, downregulation is reversible upon abstinence: this reversal is more rapid in striatum and midbrain than in cortical regions. 20 Whether chronic cannabinoid exposure downregulates CB 1 receptor signaling in human brain is unknown, although such downregulation has been hypothesized to underlie the development of tolerance to some effects of cannabis in heavy smokers. 4 Lack of methods to accurately quantify CB 1 receptors in human brain in vivo has hindered progress in answering this question. We recently developed a method to quantify cannabinoid CB 1 receptors in human brain with positron emission tomography (PET) using a novel inverse agonist radioligand, [ 18 F]FMPEP-d 2 . 22, 23 This radioligand has high affinity and selectivity for the CB 1 receptor and, in monkey brain, the vast majority of the signal represents specific binding to CB 1 receptors. 22 In human brain, -d 2 has high brain uptake, and binding  can be reliably measured as the distribution volume  (V T ) , which is proportional to receptor density. 22 To determine whether heavy cannabis smoking downregulates cannabinoid CB 1 receptors in human brain, we measured CB 1 receptors using PET and [ 18 F]FMPEP-d 2 in chronic daily cannabis smokers (N = 30 subjects) and in control subjects with minimal lifetime exposure to cannabis (N = 28 subjects). Cannabis smokers were scanned twice: immediately after chronic daily cannabis smoking, and after B4 weeks of abstinence on a monitored unit. Based on animal experiments, we hypothesized that CB 1 receptor binding is decreased in chronic daily cannabis smokers at baseline but recovers to normal levels after abstinence.
Subjects and methods
The National Institutes of Health (NIH) Central Nervous System Institutional Review Board approved the protocol and the consent forms. Written informed consent was obtained from all subjects.
Study design
We admitted male chronic daily cannabis smokers to a closed and monitored in-patient research unit for B4 weeks. We imaged cannabis smokers with PET and [
18 F]FMPEP-d 2 at two time points-namely, on the day following an evening admission and after B4 weeks of abstinence. The time of first PET scan was chosen to maximize the effect size of the hypothesized downregulation while avoiding both acute intoxication and withdrawal symptoms. Healthy control male subjects underwent a single PET scan. To examine downregulation in cannabis smokers at baseline, we compared V T of [ 18 F]FMPEP-d 2 at baseline between cannabis smokers and control subjects (between-subject comparison). To examine whether downregulation is reversible upon abstinence, we compared V T before and after abstinence in cannabis smokers (within-subject comparison).
Subjects
A total of 30 male subjects who smoked cannabis daily but who were not seeking treatment were recruited by the National Institute on Drug Abuse (Table 1) . Participants smoked an average of 10 ± 6 joints or blunts per day (range 1-30) for 12 ± 7 years (range 4-37). Age of first cannabis smoking was 15±3 years (range [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The participants underwent history and physical examination as well as laboratory tests of blood and urine to ensure that they were free of current somatic and psychiatric illness and did not currently abuse drugs other than cannabis. Urine drug tests were positive for cannabinoids in these subjects at admission. In addition, 24 cannabis smokers (80%) also smoked tobacco.
Control male subjects (N = 28) were recruited by the National Institute of Mental Health in Bethesda, MD. All subjects were free of somatic and psychiatric illness as confirmed by history, physical examination, electrocardiogram and blood and urine tests. Urine samples were negative for cannabinoids, opiates, amphetamines, cocaine metabolites and benzodiazepines. Control subjects had < 10 lifetime exposures to cannabis and no use in the preceding 3 months. One control subject (4%) smoked tobacco. Control subjects used slightly less alcohol than cannabis smokers (Table 1) .
Residential stay and assessments in cannabis smokers
Cannabis smokers were admitted to the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU) in Baltimore, MD. BPRU has a secure, continuously monitored research unit with nursing personnel present 24 h a day. Subjects were not allowed to leave the unit or receive visitors during their stay to exclude illicit drug use. Subjects were transported to the NIH Clinical Center for PET imaging on the day following an evening admission and again after B4 weeks, as well as once for magnetic resonance imaging of the brain. Urine samples were tested before leaving the unit, at arrival to NIH and after returning to the unit to ensure abstinence from drugs. Psychological and (Table 1) , images were acquired for 120 min using an Advance camera (GE Healthcare, Milwaukee, WI, USA) as previously described. 22 Blood samples were drawn from the radial artery at 15 s intervals until 2 min, then at 3 and 5 min, followed by 3 to 6 ml samples at 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 min. Plasma timeactivity curve was corrected for the fraction of unchanged radioligand by radio-high-performance liquid chromatography separation, 25 and the plasma free fraction was measured using ultrafiltration. 26 PET images were analyzed by applying a template of volumes of interest 27 as implemented in PMOD, version 3.0 (PMOD Technologies, Zurich, Switzerland), 28 in the standard stereotactic space 29 (see Supplementary Material for details). Distribution volume (V T ) was estimated according to the twotissue compartmental model 30 with concentration of parent radioligand in plasma as input function, using PMOD, as previously described. 22 Statistical analysis of V T data Data were analyzed using SPSS Statistics 17.0 for Windows (Release 17.0.0, copyright SPSS, 1993-2007, Chicago, IL, USA). V T had normally distribution (Shapiro-Wilk test) and homogeneous variance across groups (Levene's test). Behavioral data were nonnormally distributed. To test whether CB 1 receptors are decreased in cannabis smokers at baseline, we applied a repeated measures analysis of variance with group status as a between-subject factor and brain region as a within-subject factor. Body mass index (BMI) entered the model as a covariate as it was different between the groups (Table 1) . Correlations with clinical variables were assessed with the nonparametric Spearman's correlation coefficients (r) and BMI-adjusted V T . For correlations and visualizations, V T was adjusted for each subject to the average BMI in the whole sample as follows:
, where b is the slope of the regression line between V T and BMI in control subjects. To test whether CB 1 receptors increased after abstinence from cannabis, we applied a repeated measures analysis of variance with repetition (before and after abstinence) and brain region as within-subject factors. The P-values < 0.05 were considered statistically significant.
Voxel-wise analysis of V T To confirm results from volume-of-interest analysis and to explore regional specificity of findings, we compared baseline parametric V T maps between groups at voxel level using SPM5 (Wellcome Trust Centre for Neuroimaging, University College London, London, UK) (see Supplementary Material for details).
Results

At baseline, V T of [
18 F]FMPEP-d 2 was lower in cannabis smokers than in control subjects in a region-specific manner (group Â region interaction: F = 6.5, P = 0.0001). BMI-adjusted V T was B20% lower in neocortex and limbic cortex, but not in other brain regions (basal ganglia, midbrain, thalamus, pons, or cerebellum; Figures 1 and 2 ). This finding was confirmed by an independent statistical parametric mapping analysis of voxel-wise V T values, showing significantly lower cortical V T in cannabis smokers (Figure 3 ). Among the cannabis smokers, years of cannabis smoking correlated negatively with V T in cortical regions: subjects who had smoked cannabis for longer had smaller V T than subjects who had smoked cannabis for a shorter time ( Supplementary  Figure 1) . This correlation was not confounded by effects of age on V T , because V T did not correlate with age in control subjects. Current daily amounts of cannabis smoking or age of first cannabis smoking did not correlate with V T .
In addition, V T was not significantly correlated with withdrawal or craving measured on admission (for example, in the anterior cingulate cortex: withdrawal, r = 0.06, P = 0.762; craving, r = À0.07, P = 0.773) or as the mean value of these two scales for entire residential stay of B4 weeks (for example, in the anterior cingulate cortex: withdrawal, r = À0.33, P = 0.077; craving, r = À0.05, P = 0.805). In addition, the change of V T during the residential stay was not significantly correlated with the change in withdrawal (for example, in the anterior cingulate cortex: r = 0.04, P = 0.904) or craving (for example, in the anterior cingulate cortex: r = 0.23, P = 0.431).
Ethnicity may affect V T of [
as three control subjects of Indian descent had unusually low V T values, whereas no difference was found between African-American and Caucasian subjects of European descent (Supplementary Figure 2) . There were no cannabis smokers of Indian descent. These three control subjects were not excluded from the analysis, but if they were excluded, the group Â region interaction would become stronger (F = 9.4, P = 0.0000002).
BMI had a main effect on V T in all regions (F = 8.1, P = 0.006); in both groups, higher BMI was associated with lower V T . BMI did not correlate with the plasma free fraction of [ Only free (non-protein bound) radioligand in arterial plasma is able to enter the brain. However, smaller V T in cannabis smokers than in control subjects was not caused by smaller fraction of free radioligand in arterial plasma, as this fraction was similar between groups (Table 1) .
Tobacco smoking was more prevalent among cannabis smokers than among control subjects. However, a repeated measures analysis of variance did not show a main effect of tobacco smoking (F < 0.01, P = 0.998) or a tobacco smoking Â region interaction (F = 0.48, P = 0.735) on V T among cannabis smokers. In addition, when smoking was taken as a covariate in the overall model, the group Â region interaction remained F]FMPEP-d 2 at baseline was unchanged in cerebellum (À2%, P = 0.703, two-tailed t-test; a), but decreased in anterior cingulate cortex (À21%, P = 0.0005, two-tailed t-test; b) in chronic daily cannabis smokers (n = 30) compared with control subjects (n = 28). Ratio of V T in anterior cingulate cortex to that in cerebellum decreased variance in both groups and showed a more significant reduction in cannabis smokers (À20%, P = 0.0000001, two-tailed t-test; c).
significant (F = 3.2, P = 0.017). Similarly, when the analysis was covaried for alcohol use, the groupregion interaction remained significant (F = 6.6, P = 0.00009). Thus, neither tobacco nor alcohol use were likely to significantly confound the main finding.
As V T in cerebellum was similar between groups, we used cerebellum as a reference region to estimate binding in other regions of the brain. Although the majority of uptake in cerebellum represented specific binding, normalizing uptake in cortical regions to that in cerebellum for each subject was expected to reduce variability and to increase statistical power. For example, as BMI correlated with V T in all regions, such normalization would cancel the effects of BMI. We found that uptake normalized to cerebellum was B20% lower in cannabis smokers than in control subjects in cortical regions, but not in caudate nucleus, midbrain, thalamus or pons (group Â region interaction: F = 8.0, P = 0.0000002).
To determine whether decreased V T in cannabis smokers is reversible, we repeated PET measurements in 14 cannabis smokers after 26 ± 5 days of monitored abstinence (range 13-32 days). After monitored abstinence, V T increased specifically in those brain regions that had shown decreased V T at baseline (repetition Â region interaction: F = 3.33, P = 0.037; Figure 4 ) except for hippocampus. At baseline, V T was not different between subjects who had two PET scans (N = 14) and those who had one (N = 16; main effect of completer status: F = 0.16, P = 0.691; completer status Â region interaction: F = 0.43, P = 0.770), which argues against selection bias. Change in V T did not correlate with any of the clinical variables, such as current amount or years of cannabis smoking, or with the interval between the two PET scans. Fraction of free radioligand in arterial plasma did not change after abstinence (P = 0.971).
Discussion
We found that V T of [ 18 F]FMPEP-d 2 at baseline was B20% lower in chronic, daily cannabis smokers than in control subjects in cortical, but not in subcortical brain regions. V T was also negatively correlated with years of cannabis smoking: subjects who had smoked cannabis longer had lower V T than subjects who had smoked for a shorter time. Finally, V T increased in cannabis smokers after B4 weeks of abstinence. We interpret these findings as reflecting changes in CB 1 receptor density. Our findings are unaffected by group differences in peripheral distribution and metabolism of the radioligand, because the outcome measure V T corrects for these effects. These findings confirm that chronic cannabis exposure reversibly downregulates CB 1 receptors in humans, similar to its effects in rodents. Region-specific decrease in CB 1 receptor binding may be part of neuroadaptations promoting development of cannabis dependence in chronic daily smokers.
Decreased V T in cannabis smokers likely reflects a change in CB 1 receptors (or affinity) rather than a confounding effect of an endogenous (for example, anandamide) or exogenous (for example, D 9 -THC) agonist. Daily cannabis smokers have prolonged clearance of cannabinoids from the body, [31] [32] [33] and hence these subjects may have had cannabinoids present also in the brain during the first PET scan. Some PET radioligands are sensitive to changes in concentration of endogenous neurotransmitters, such that increased neurotransmitter concentration causes reduced binding of the radioligand. 34 Whether D 35 consistent with large receptor reserve. Nevertheless, CB 1 receptor occupancy by D
9
-THC or its metabolites remains a potential confound. Another potential confound is a change in G-protein coupling of the CB 1 receptor (desensitization), which has been documented in rodent studies. The radioligand [ 18 F]FMPEP-d 2 is an inverse agonist and presumably labels receptors in both high-and low-affinity states, as binding of another structurally related inverse agonist, rimonabant, is not affected by guanyl nucleotide modulation in rat brain tissue in vitro. 36 Therefore, [ 18 F]FMPEP-d 2 is unlikely to detect CB 1 receptor desensitization that occurs after chronic agonist exposure in rodents. 15 Although our results suggest changes in CB 1 receptor density, our PET measurement cannot distinguish a change in receptor density and affinity. However, rodent studies suggest a change in receptor density rather than affinity. Our findings of reversible and regionally selective downregulation of CB 1 receptors parallel those from a large number of rodents studies. 15 These studies demonstrated substantial downregulation of CB 1 receptors because of loss of CB 1 receptor protein after chronic agonist exposure. 15, 20 One post-mortem study in humans also reported CB 1 receptor downregulation in cannabis smokers that was greatest in hippocampus and least in globus pallidus and substantia nigra. 37 The regional selectivity of downregulation is strikingly similar between rodents and humans in the current study: no significant downregulation was found in the basal ganglia and the midbrain in humans. Furthermore, we did not find downregulation in cerebellum, which is consistent with rodent studies showing less downregulation in this area compared with hippocampus. 16, 21 The reasons for regional selectivity are unclear, but rodent studies suggest regional differences in distribution of markers of CB 1 receptor signaling, such as G-protein subunits, subtypes of adenylyl cyclase, receptor kinases, arrestins and other proteins associated with receptor signaling. 15, 20, 38 Could CB 1 receptor downregulation be a mechanism for tolerance to cannabis in humans? That is, could regional differences in receptor downregulation predict differential development of tolerance toward various effects of cannabis? Interestingly, chronic daily cannabis smokers are tolerant to most, but not all, effects of cannabis. For example, tolerance develops for memory impairment, 4, 5 but not for feeling of high 4, 5 or motor impairment, 5 induced by both intravenous and smoked D 9 -THC. Feelings of high and motor impairment might be driven by CB 1 receptors in the basal ganglia, midbrain and cerebellum-regions that did not show receptor downregulation in the current study. Another interesting finding is that hippocampus did not show reversal of downregulation after abstinence: prolonged downregulation might contribute to long-term cognitive impairment in chronic daily cannabis smokers noted by some studies. 39 This hypothesis, however, is simplistic because CB 1 receptors are widespread in the human brain and complex psychological effects of cannabis are probably not limited to receptors in one particular brain region. In addition, CB 1 receptor desensitization, which we cannot measure, may still occur in these regions despite unchanged receptor density. Finally, we did not objectively measure tolerance to cannabis. We only measured withdrawal and craving, neither of which correlated with CB 1 receptor binding. Future studies should establish the relationship between tolerance to cannabis and regional CB 1 receptor downregulation.
We found decreased CB 1 receptor binding in subjects who had smoked large amounts of cannabis daily for years. Even in these heavy smokers, binding returned to normal levels in most regions after B4 weeks of abstinence. We are unsure whether moderate and occasional cannabis smoking would produce similar downregulation. Considering that occasional cannabis smokers do not develop tolerance to the extent that chronic daily smokers do, 40 downregulation of CB 1 receptors may be smaller in occasional smokers, assuming that receptor downregulation contributes to tolerance. Nevertheless, future studies should specifically address that question by measuring CB 1 receptor binding in occasional cannabis smokers.
Tobacco smoking was more prevalent among cannabis smokers than among control subjects. However, tobacco smoking is unlikely to explain the regionspecific and reversible decrease in CB 1 receptor binding in cannabis smokers, because tobacco smoking had no effects on V T in cannabis smokers or on the group Â region interaction in the overall model. In addition, V T increased after B4 weeks of abstinence from cannabis, even though subjects continued smoking tobacco during that time. Nevertheless, future studies should examine the effects of tobacco smoking on CB 1 receptor binding in control subjects who do not smoke cannabis.
BMI correlated negatively with [ 18 F]FMPEP-d 2 V T in both groups, such that people with higher BMI tended to have lower V T than people with lower BMI. Although the cause of this association is unclear, we doubt that it represents an association with CB 1 receptor density. Brain CB 1 receptors are implicated in feeding behaviors.
41 CB 1 receptor stimulation in mouse brain can both promote and inhibit feeding behavior, depending on the dose of the agonist and the brain region involved. 42 However, we found similar correlations in all brain regions, not restricted to those implicated in feeding behavior. Therefore, we suspect that this correlation is driven by some peripheral confound-potentially the fraction of free radioligand in plasma. For [
18 F]FMPEP-d 2 , this fraction is very small ( < 1%) and imprecisely measured. 22 Although we found no correlation between BMI and the measured plasma free fraction, a small but significant correlation cannot be excluded. The primary finding of decreased V T in cannabis smokers was region specific and therefore not likely confounded by the plasma free fraction that would affect V T globally. Of note, the outcome measure V T corrects for peripheral metabolism and disposition of the radioligand, which makes these factors unlikely confounders. The important implication of this finding is that BMI should be taken as a covariate in [ 18 F]FMPEP-d 2 studies, whatever the underlying mechanism.
In conclusion, we report for the first time decreased CB 1 receptor binding in cortical, but not in subcortical, brain regions in chronic daily cannabis smokers, and that this downregulation is reversible after B4 weeks of abstinence. Downregulation of CB 1 receptors may underlie tolerance to effects of cannabis, and may provide insight into the role of CB 1 receptors in diseases that are associated with chronic cannabis smoking, such as psychosis and depression. Future studies should determine whether occasional cannabis smokers or females show similar downregulation, and examine the time course of reversal of downregulation in greater detail.
